CD8A and neoplasm: Collectively, this discovery reveals two important mechanisms to enhance anti-tumor immunity by co-targeting (i) anti-YTHDF1 therapy: where, YTHDF1-deficiency protect ‘antigen-degradation’ and allows efficient recognition and presentation by DCs, in-turn, further increases the abundance of DC-mediated effector CD8+T-cells by cross-presentation mechanism, supported by Ding et al., 2021 [169] and (ii) by enhancing anti-PD-1/PD-L1 efficacy: which further potentiates the efficacy of anti-PD-1 immunotherapy by enhancing the effector function of CD8+T-cells in the TME [159] Figure 7.